Pharmaceutical Discount Agreements
Original notice title
Germany – Pharmaceutical products – Arzneimittelrabattverträge gem. § 130a Abs. 8 SGB V im Rahmen von Open-House-Verfahren
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
40 / 100
Risk factors
As an open-house agreement, there is no minimum purchase obligation. The buyer may not purchase any volume under the ag...
If exclusive discount agreements for the same active substance are concluded via other procedures, the open-house contr...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 3 lots
- Duration until Apr 2027
- Supply of pharmaceutical products for 21 active substances as listed in lots.
- Non-exclusive discount agreements under §130a SGB V with uniform, non-negotiable terms.
Show full summary
IKK classic is conducting an open-house procedure for non-exclusive pharmaceutical discount agreements under §130a SGB V for 21 specific active substances. The procedure allows any eligible pharmaceutical company to join at any time until March 2027, under uniform, non-negotiable terms. The contract period is from May 2025 to April 2027, with possible extension. No estimated contract value is provided. Submission is via email with required documents including self-declarations and a commercial register extract. The procedure is not a traditional competitive tender; all eligible participants who submit required documents can enter the agreement.
Risks
As an open-house agreement, there is no minimum purchase obligation. The buyer may not purchase any volume under the ag...
If exclusive discount agreements for the same active substance are concluded via other procedures, the open-house contr...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical entrepreneurs (or consortia) as defined in §4(18) AMG are eligible.
Administrative
- Submission of signed contract, self-declarations, and a commercial register extract not older than 6 months at contract start.
- All documents must be submitted via email to [email protected].
Requirements may be incomplete.
Buyer
Lots (21)
LOT-0001
Apomorphine; ATC: N04BC07
Non-exclusive discount agreement for Apomorphine (ATC N04BC07). Supply of pharmaceutical product.
Location
Duration
Category
Deadline
Award details
Apomorphin
ATC-Code: N04BC07
Show original TED data
Original lot title
Apomorphin; ATC-Code: N04BC07
Original TED description
Apomorphin; ATC-Code: N04BC07
LOT-0002
Baclofen; infusion solution; ATC: M03BX01
Non-exclusive discount agreement for Baclofen infusion solution (ATC M03BX01).
Location
Duration
Category
Deadline
Award details
Baclofen
Infusionslösung
ATC-Code: M03BX01
Show original TED data
Original lot title
Baclofen; Infusionslösung; ATC-Code: M03BX01
Original TED description
Baclofen; Infusionslösung; ATC-Code: M03BX01
LOT-0003
Betamethasone and Gentamicin; ATC: D07CC01
Non-exclusive discount agreement for Betamethasone and Gentamicin (ATC D07CC01).
Location
Duration
Category
Deadline
Award details
Betamethason und Gentamicin
ATC-Code: D07CC01
Show original TED data
Original lot title
Betamethason und Gentamicin; ATC-Code: D07CC01
Original TED description
Betamethason und Gentamicin; ATC-Code: D07CC01
LOT-0004
Budesonid; Hartkapseln mit veränderter Wirkstofffreisetzung; Kombipackung; ATC-Code: A07EA06
Budesonid; Hartkapseln mit veränderter Wirkstofffreisetzung; Kombipackung; ATC-Code: A07EA06
Location
Duration
Category
Award details
Budesonid
Hartkapseln mit veränderter Wirkstofffreisetzung
Kombipackung
ATC-Code: A07EA06
LOT-0005
Cariprazin; ATC-Code: N05AX15
Cariprazin; ATC-Code: N05AX15
Location
Duration
Category
Award details
Cariprazin
ATC-Code: N05AX15
LOT-0006
Dydrogesteron und Estradiol; ATC-Code: G03FA14
Dydrogesteron und Estradiol; ATC-Code: G03FA14
Location
Duration
Category
Award details
Dydrogesteron und Estradiol
ATC-Code: G03FA14
LOT-0007
Dydrogesteron und Estradiol; ATC-Code: G03FB08
Dydrogesteron und Estradiol; ATC-Code: G03FB08
Location
Duration
Category
Award details
Dydrogesteron und Estradiol
ATC-Code: G03FB08
LOT-0008
Formoterol und Aclidiniumbromid; ATC-Code: R03AL05
Formoterol und Aclidiniumbromid; ATC-Code: R03AL05
Location
Duration
Category
Award details
Formoterol und Aclidiniumbromid
ATC-Code: R03AL05
LOT-0009
Indacaterol und Mometason; ATC-Code: R03AK14
Indacaterol und Mometason; ATC-Code: R03AK14
Location
Duration
Category
Award details
Indacaterol und Mometason
ATC-Code: R03AK14
LOT-0010
Indacaterol, Glycopyrroniumbromid und Mometason; ATC-Code: R03AL12
Indacaterol, Glycopyrroniumbromid und Mometason; ATC-Code: R03AL12
Location
Duration
Category
Award details
Indacaterol, Glycopyrroniumbromid und Mometason
ATC-Code: R03AL12
LOT-0011
Lisdexamfetamin; Hartkapseln; Packungsgröße: 100; ATC-Code: N06BA12
Lisdexamfetamin; Hartkapseln; Packungsgröße: 100; ATC-Code: N06BA12
Location
Duration
Category
Award details
Lisdexamfetamin
Hartkapseln
Packungsgröße: 100
ATC-Code: N06BA12
LOT-0012
Methylphenidat; Hartkapseln mit veränderter Wirkstofffreisetzung; Packungsgrößen: 27, 36, 63 und 99; ATC-Code: N06BA04
Methylphenidat; Hartkapseln mit veränderter Wirkstofffreisetzung; Packungsgrößen: 27, 36, 63 und 99; ATC-Code: N06BA04
Location
Duration
Category
Award details
Methylphenidat
Hartkapseln mit veränderter Wirkstofffreisetzung
Packungsgrößen: 27, 36, 63 und 99
ATC-Code: N06BA04
LOT-0013
Methylphenidat; Retardtabletten; Packungsgröße: 29 ; ATC-Code: N06BA04
Methylphenidat; Retardtabletten; Packungsgröße: 29 ; ATC-Code: N06BA04
Location
Duration
Category
Award details
Methylphenidat
Retardtabletten
Packungsgröße: 29
ATC-Code: N06BA04
LOT-0014
Nebivolol; ATC-Code: C07AB12
Nebivolol; ATC-Code: C07AB12
Location
Duration
Category
Award details
Nebivolol
ATC-Code: C07AB12
LOT-0015
Oxybutynin; transdermale Pflaster; ATC-Code: G04BD04
Oxybutynin; transdermale Pflaster; ATC-Code: G04BD04
Location
Duration
Category
Award details
Oxybutynin
transdermale Pflaster
ATC-Code: G04BD04
LOT-0016
Pilocarpin; ATC-Code: N07AX01
Pilocarpin; ATC-Code: N07AX01
Location
Duration
Category
Award details
Pilocarpin
ATC-Code: N07AX01
LOT-0017
Prednisolon; Anwendung am Auge; ATC-Code: S01BA04
Prednisolon; Anwendung am Auge; ATC-Code: S01BA04
Location
Duration
Category
Award details
Prednisolon
Anwendung am Auge
ATC-Code: S01BA04
LOT-0018
Raltegravir; ATC-Code: J05AJ01
Raltegravir; ATC-Code: J05AJ01
Location
Duration
Category
Award details
Raltegravir
ATC-Code: J05AJ01
LOT-0019
Rifampicin; ATC-Code: J04AB02
Rifampicin; ATC-Code: J04AB02
Location
Duration
Category
Award details
Rifampicin
ATC-Code: J04AB02
LOT-0020
Sulfadiazin silber; ATC-Code: D06BA01
Sulfadiazin silber; ATC-Code: D06BA01
Location
Duration
Category
Award details
Sulfadiazin silber
ATC-Code: D06BA01
LOT-0021
Vemurafenib; ATC-Code: L01EC01
Vemurafenib; ATC-Code: L01EC01
Location
Duration
Category
Award details
Vemurafenib
ATC-Code: L01EC01
Procurement Details
- Publication date
- 13 Mar 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 167295-2025
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
40 / 100
Risk factors
As an open-house agreement, there is no minimum purchase obligation. The buyer may not purchase any volume under the ag...
If exclusive discount agreements for the same active substance are concluded via other procedures, the open-house contr...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications